Armata Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) is a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics to treat antibiotic-resistant and difficult-to-treat bacterial infections. Utilizing its proprietary bacteriophage-based technology platform, the company is advancing a pipeline of natural and synthetic phage candidates targeting major pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus. Armata's capabilities span from bench research to clinical development, supported by its in-house, phage-specific GMP manufacturing facility.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Initiating and conducting a Phase 3 pivotal clinical trial evaluating AP-SA02 as an adjunct to best available antibiotic therapy for the treatment of complicated Staphylococcus aureus bacteremia.
Expected impact: A successful trial would support a future Biologics License Application (BLA) submission and establish the first randomized controlled evidence of phage therapy efficacy.
Commissioning and operating a 56,000 square foot state-of-the-art, phage-specific current Good Manufacturing Practices (cGMP) manufacturing facility in Los Angeles, California.
Expected impact: Provides full end-to-end control over clinical and commercial-scale production, ensuring high purity, stability, and compliance with FDA CMC requirements.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
A multi-year research collaboration to discover, develop, and commercialize proprietary synthetic bacteriophage candidates targeting key infectious disease pathogens.
Terms: Specific financial terms remain undisclosed.
Innoviva is Armata's largest shareholder (holding an 82.7% stake) and primary financial backer, providing critical credit facilities to fund late-stage clinical trials and extend the company's cash runway.
Terms: Includes a $25.0 million secured credit agreement entered into on May 12, 2026, bearing a 14.0% annual interest rate and maturing on January 11, 2029, alongside previous credit agreements extended to mature on June 1, 2027.